Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid LeukemiaLu Zhang, Yu Shen, Tianyu Cai et al.|Molecular Cancer Therapeutics|2021Cited by 34
Data from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid LeukemiaLu Zhang, Yu Shen, Tianyu Cai et al.|Unknown|2023Cited by 0
Data from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid LeukemiaLu Zhang, Yu Shen, Tianyu Cai et al.|Unknown|2023Cited by 0
Supplementary Data from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid LeukemiaLu Zhang, Yu Shen, Tianyu Cai et al.|Unknown|2023Cited by 0
Figure S2 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid LeukemiaLu Zhang, Yu Shen, Tianyu Cai et al.|Unknown|2023Cited by 0